Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INCB024360 versus tamoxifen in biochemical-recurrent-only ovarian, primary peritoneal, or fallopian tube cancer
2012-001472-10Phase 2Terminated
- Sponsor
- Incyte
- Start
- May 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of epacadostat in Ovarian Epithelial Adenocarcinoma, primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC) (2 arms), sponsored by Incyte. Primary endpoint: Progression-free survival. Started May 2012; status: terminated.
02
Drugs
epacadostat
03
Conditions
Ovarian Epithelial Adenocarcinomaprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on 2012-001472-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001472-10.